An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

Trial Profile

An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Rogaratinib (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Head and neck cancer; Lung cancer; Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 12 Sep 2017 Results from phase-I expansion cohort in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels, presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results (n=72) assessing clinical responses in FGFR-positive patients selected by a novel mRNA-based strategy, presented at the 42nd European Society for Medical Oncology Congress
    • 11 Sep 2017 Planned End Date changed from 29 Mar 2019 to 2 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top